CrownBio offers a collection large enough to be representative of the histological and genetic diversity seen in the patient population in ongoing clinical trials.
CrownBio’s newly established models have been trialed with a range of EGFR inhibitors – including I, II, and III generation TKIs as well as Erbitux® – and their poor response to therapy mirrors the...
With the best-in-class RCB generation capabilities of Selexis on board, the existing knowledge and infrastructure for the manufacturing of therapeutic monoclonal antibodies is optimally leveraged.
"Selexis expertise will be an added value for our molecule,” said Antonio Francesco Di Naro, PhD, Founder, and CEO of ADIENNE Pharma & Biotech. “This collaboration will be fruitful for our company.”
3 of 3
Receive JSR Life Sciences news on your RSS reader.